The insider selling is trivial in size and likely tied to equity grant vesting, not a negative signal. Monitor for any upcoming earnings or pipeline catalysts that could move the stock, but this cluster alone does not warrant action.
How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Jun 8 $6.24entry
- T+1 · 5mo ago +4.17%α +4.46% · $6.50
- T+5 · 5mo ago +10.26%α +8.14% · $6.88
- T+20 · 4mo ago +34.13%α +32.50% · $8.37
- T+60 · 3mo ago +35.10%α +32.04% · $8.43
Price Chart
How similar events traded
Executive Summary
A cluster of insider selling at Xeris Biopharma, totaling $192K in open-market sales by two directors and an officer, occurred alongside large non-cash equity grants to four directors. The sales represent ~0.017% of the $1.1B market cap, a trivial amount, and are likely liquidity-driven following the vesting of restricted stock grants. No material bearish signal is present.
Key Financial Metrics
Key Facts
- Three insiders sold a total of $192K in open-market sales: Director John Johnson ($91K), Director Dawn Halkuff ($122K), and Officer Beth Hecht ($101K).
- Four directors received non-cash equity grants totaling ~$609K in value (at $6.15/share) and additional zero-value grants.
- Total open-market sales represent ~0.017% of the $1.1B market cap, well below the 0.1% threshold for materiality.
- Sales occurred on the same day as large equity grants, suggesting a routine pattern of selling to cover tax obligations or diversify after vesting.
Financial Impact
Open-market sales of $192K, or ~0.017% of market cap, are immaterial relative to company size.
Risk Factors
- No material risk identified from this insider activity; the cluster is routine and non-informative.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CLUSTER Data (Synthetic) | cluster-XERS-1780697908162 |
Track record
25 reports on XERS
4 of 4 bullish or bearish reports moved the stock their way by T+20. Best: +45.52% at T+60 after the Aug 6, 2026 report. 5 of 5 went positive at some point.
Filters
- Nov 6, 202610d ago Insider Cluster Neutral 2/10 Entry $15.86 Now $16.70 +5.30% settles Dec 8
- Nov 5, 202611d ago 144 Neutral 2/10 Entry $15.20 Now $16.70 +9.87% settles Dec 7
- Nov 5, 202611d ago 8-K Bullish 6/10 Entry $13.08 Now $16.70 +27.68% settles Dec 4
- Nov 4, 202612d ago Insider Cluster Neutral 2/10 Entry $13.08 Now $16.70 +27.68% settles Dec 4
- Nov 4, 202612d ago 3 Neutral 2/10 Entry $13.08 Now $16.70 +27.68% settles Dec 4
- Nov 2, 202614d ago 144 Neutral 2/10 Entry $10.35 Now $16.70 +61.35% settles Dec 2
- Nov 2, 202614d ago 8-K Neutral 2/10 Entry $10.17 Now $16.70 +64.21% settles Dec 1
- Oct 30, 202617d ago SC 13G/A Neutral 2/10 Entry $10.71 Now $16.70 +55.93% settles Nov 30
- Oct 14, 20264w ago 8-K Neutral 3/10 Entry $9.77 to $16.52 Now $16.70 +70.93% ▲ +69.09% +70.36% vs SPY
- Oct 2, 20266w ago Insider Cluster Neutral 3/10 Entry $10.13 to $10.71 Now $16.70 +64.86% ▲ +5.73% +8.19% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers